Accelerating rapid test development for COVID-19 through manufacturing scale up and open collaboration

The COVID-19 pandemic has brought unprecedented challenges to the in vitro diagnostics industry and provided a unique opportunity to demonstrate the value of diagnostic testing and a strong diagnostics industry. Diagnostic companies are responding to the demand for the accelerated development of accurate, affordable tests and a rapid, orders-of-magnitude increase in manufacturing capacity through open, pre-competitive collaboration with multiple stakeholders. This includes early stageIVD companies through to established global corporations, supply chain, governments, regulatory agencies, public and private funding bodies and national healthcare systems.

Learning Objectives:

• Highlights specific examples of the unique challenges being faced by the diagnostics industry
• Review how a collaborative approach is addressing these challenges
• Outline why a stronger diagnostics industry will be one of the enduring legacies of the COVID-19 pandemic